Sibeprenlimab治疗IgA肾病:VISIONARY试验的原理与基线数据
VISIONARY是一项多中心、双盲、安慰剂对照的3期试验,旨在评估选择性APRIL抑制剂Sibeprenlimab在活检确诊IgA肾病患者中的疗效与安全性。本文报告了试验设计及510例入组患者的基线特征,患者来自31个国家,主要终点为9个月时24小时尿蛋白肌酐比相较基线的变化。
要点
- Sibeprenlimab为选择性APRIL抑制剂,可减少致病性Gd-IgA1产生及免疫复合物形成。
- VISIONARY试验纳入510例活检确诊IgA肾病患者,随机1:1接受皮下Sibeprenlimab 400 mg或安慰剂每4周一次共26次。
- 主要终点为9个月时24小时尿蛋白肌酐比相较基线的变化。
核心结论
- VISIONARY是迄今规模最大的IgA肾病试验,正在广泛代表性且高进展风险IgA肾病人群中评估皮下Sibeprenlimab的疗效与安全性。
研究设计与样本
- 多中心、双盲、安慰剂对照3期试验(NCT05248646),纳入活检确诊IgA肾病的成人患者510例,来自31个国家。
- 患者随机1:1接受皮下Sibeprenlimab 400 mg或安慰剂,每4周一次,共26次。
- 主要终点为9个月时24小时尿蛋白肌酐比(uPCR-24 h)相较基线的变化。
主要发现
- 510例入组患者中,58.8%为男性,59.0%为亚洲人,57.3%居住于东亚或南亚/东南亚。
- 中位年龄42.0岁(范围18.0-83.0岁);97.8%使用肾素-血管紧张素系统抑制剂(RASi),45.1%使用钠-葡萄糖共转运蛋白2抑制剂(SGLT2i)。
- 基线uPCR-24 h均值(SD)为1.54(0.92)g/g;基线尿蛋白均值(SD)为2.1(1.3)g/d;基线eGFR均值(SD)为64.2(25.3)ml/min per 1.73 m2。
临床怎么用
- 该试验针对高进展风险IgA肾病患者,背景治疗中RASi使用率达97.8%,SGLT2i使用率达45.1%,提示当前标准治疗背景。
- 主要终点采用9个月时24小时尿蛋白肌酐比变化,可作为评估IgA肾病新型靶向治疗短期疗效的参考指标。
局限性
- 本文仅报告VISIONARY试验的设计与基线数据,尚未报告Sibeprenlimab的疗效与安全性结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: IgA nephropathy is the most common primary glomerulonephritis and a leading cause of kidney failure worldwide. Treatments that target the underlying immune drivers of the disease to improve long-term patient outcomes are needed. Sibeprenlimab, a selective A Proliferation-Inducing Ligand (APRIL) inhibitor that significantly decreases pathogenic galactose-deficient IgA1 (Gd-IgA1) production and immune complex formation, is being investigated in the ongoing phase 3 VISIONARY trial. Here, we summarize the overall study design and report on the baseline characteristics of patients enrolled in the trial. METHODS: VISIONARY is a multicenter, double-blind, placebo-controlled trial (ClinicalTrials.gov identifier, NCT05248646; study date of registration: 2022-02-18). Adults with biopsy-confirmed IgA nephropathy were randomized 1:1 to receive subcutaneous (s.c.) sibeprenlimab 400 mg or placebo once every 4 weeks for 26 doses. The primary end point is the 24-hour urine protein-to-creatinine ratio (uPCR-24 h) at 9 months compared with the baseline. RESULTS: Of 510 enrolled patients across 31 countries, 58.8% were male, 59.0% were Asian, and 57.3% lived in East or South/Southeast Asia. The median age was 42.0 (range, 18.0-83.0) years; 97.8% of patients were using renin-angiotensin system inhibitors (RASis), and 45.1% were using sodium-glucose cotransporter 2 inhibitors. The mean (SD) baseline uPCR-24 h was 1.54 (0.92) g/g. The mean (SD) baseline urine protein was 2.1 (1.3) g/d, and the mean (SD) baseline estimated glomerular filtration rate (eGFR) was 64.2 (25.3) ml/min per 1.73 m2. CONCLUSION: VISIONARY, the largest IgA nephropathy trial to date, is evaluating the efficacy and safety of s.c. sibeprenlimab in a broadly representative population with IgA nephropathy at high risk of disease progression.
引用
- Perkovic V, Barratt J, Lafayette R, et al. Evaluating Sibeprenlimab in IgA Nephropathy - Rationale and Baseline Data from the VISIONARY Trial. Kidney Int Rep. 2025. PMID: 41426046. doi:10.1016/j.ekir.2025.09.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。